JTAG and UART Vulnerabilities in Medical Devices

Updated April 13, 2025

Medical device design increasingly relies on debugging tools like JTAG (Joint Test Action Group) and UART (Universal Asynchronous Receiver-Transmitter). These interfaces aren't accessories. They're built into the hardware and used throughout development, testing, and field maintenance. They're also a well-known attack surface that the FDA now expects manufacturers to address explicitly.

This post examines how JTAG and UART work in medical devices, what risks they introduce, and what the FDA's compliance requirements actually demand. Manufacturers, security engineers, and regulatory teams all need to understand this intersection clearly.

Key Takeaways

• JTAG and UART enable vital medical device debugging and maintenance.
• Unsecured debug ports pose significant cybersecurity risks.
• The FDA mandates securing all external ports, including JTAG/UART.
• Mitigation involves disabling, authenticating, and physical protection.
• Hardware-focused penetration testing identifies debug port risks.
• Design for security from development through post-market.

Table of Contents

• Key Takeaways
• Understanding JTAG and UART in Medical Devices
• The Role of Debug Ports in Medical Device Design
• FDA Compliance and Cybersecurity Considerations
• Mitigating Cybersecurity Risks
• The Future of Debug Ports and Regulatory Compliance
• JTAG and UART Vulnerability FAQs

Why this matters

The FDA's Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to JTAG and UART vulnerabilities the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023.

Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap.

Understanding JTAG and UART in Medical Devices

JTAG (Joint Test Action Group), a standardized interface for testing printed circuit boards (PCBs), is crucial in developing and maintaining medical devices. It provides a means to access, test, and verify the functionality of internal components. JTAG is primarily used in medical devices to debug complex electronic systems and ensure they perform as expected, vital for patient safety and device reliability.

UART (Universal Asynchronous Receiver-Transmitter), on the other hand, facilitates serial communication in embedded systems, which is crucial for transmitting data in medical devices. This technology is used for diagnostics, logging, and as a communication interface between different medical device components. Its asynchronous nature makes it versatile and useful in various medical applications, from patient monitoring systems to diagnostic equipment.

The Role of Debug Ports in Medical Device Design

Debug ports like JTAG and UART are built into medical device hardware from the start. They give engineers real-time visibility into device behavior, which is essential during development and useful throughout the device's service life. Without them, troubleshooting complex embedded systems would be far slower and more expensive.

The problem is that these same capabilities, direct memory access, console output, chip-level debugging, don't disappear after production. If the ports remain active and unprotected on a shipped device, an attacker with physical access has the same reach as the original developer. That's a serious control gap that needs to be closed before a device ever reaches a clinical environment.

FDA Compliance and Cybersecurity Considerations

Cyberattacks on healthcare infrastructure have increased steadily, and the FDA has responded by raising its cybersecurity expectations for all connected and software-based medical devices. Debug ports get specific attention because of how much access they grant.

Under the February 3, 2026 premarket cybersecurity guidance, manufacturers must document how they've addressed risks from all external interfaces, including debug ports. That means secure software development practices, documented threat models covering JTAG and UART attack paths, risk assessments aligned with ISO 14971, and evidence of implemented controls like access restrictions and encryption. Reviewers look for this documentation. Missing it generates deficiency letters.

Mitigating Cybersecurity Risks

Securing JTAG and UART ports requires a layered approach. Hardware controls come first: fusing or physically disabling JTAG after production, removing or covering test pads, and restricting UART console access at the firmware level. Where ports must remain active for field service, authentication should be required before any access is granted.

See also: SPDF and IEC 62304 Mapping: FDA Cyber Guide, FDA Penetration Testing Requirements for Medical Devices, and Letter to File vs New 510(k) for Cybersecurity Changes.

Secure boot mechanisms protect against firmware tampering even if a debug port is reached. Software updates should be cryptographically signed and verified on-device before installation. Regular security audits and penetration testing, focused specifically on hardware attack surfaces, are the only reliable way to confirm that these controls actually hold under adversarial conditions.

The Future of Debug Ports and Regulatory Compliance

Medical device hardware is getting more capable, and so are the tools attackers use against it. JTAG and UART security practices that were adequate five years ago may not satisfy today's FDA reviewers or resist today's threat actors. The February 3, 2026 guidance will continue to be the baseline for premarket submissions, but manufacturers should expect the bar to rise as the threat environment matures.

Staying ahead of that means treating debug port security as a live engineering concern, not a one-time design decision. Manufacturers who build security review into their product development cycles, and who document that work thoroughly, will be far better positioned for both regulatory approval and real-world resilience.

Conclusion

JTAG and UART ports are engineering tools that become security liabilities when left unmanaged. Getting the balance right requires deliberate design choices, documented risk management, and hardware-level testing that goes beyond what a typical software security review covers. Manufacturers, healthcare providers, and regulators each have a role in making sure these interfaces don't become the weak point in an otherwise sound device.

The goal hasn't changed: medical devices should enhance patient care without compromising safety or security. Achieving that goal with debug ports in play requires treating them as first-class security concerns from day one.

How Blue Goat approaches this

Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result.

Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our medical device cybersecurity services for the full scope. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.

FAQ

What are JTAG and UART interfaces?

JTAG (Joint Test Action Group) is a standard for testing and debugging hardware at the chip level. UART (Universal Asynchronous Receiver/Transmitter) is a serial communication protocol used for debugging, console access, or data transmission between components.

Why are JTAG and UART considered security risks?

These interfaces often provide low-level or privileged access to the device, bypassing traditional security controls. If left exposed or unsecured, attackers can exploit them to read memory, extract firmware, or alter system behavior.

How are these interfaces typically exposed on devices?

JTAG and UART are usually accessible through test pads, headers, or solder points on PCBs. In many embedded devices including medical and IoT systems, these interfaces remain physically accessible and active post-manufacturing.

What kind of attacks can occur through JTAG access?

Attackers can perform firmware dumping, memory manipulation, fault injection, bypass boot protections, or gain root-level shell access, all of which can compromise device integrity and patient safety in medical environments.

What can UART vulnerabilities allow an attacker to do?

UART ports often provide access to system consoles. If login is not protected or debugging features are enabled, an attacker may gain root access, disable security features, or alter system behavior undetected.

Are JTAG/UART vulnerabilities relevant to the FDA medical device submissions?

Yes. The FDA's February 3, 2026 premarket cybersecurity guidance encourages manufacturers to secure all external ports, including debug/test interfaces like JTAG and UART, to prevent unauthorized access and support risk mitigation.

About the author

Christian Espinosa, CISSP, Founder, Blue Goat Cyber. Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. Read more about Christian.